Freshfields Advises Berkeley Lights on Its Acquisition of IsoPlexis

Freshfields is advising Berkeley Lights (Nadsaq: BLI), a life sciences tools company, on its acquisition of IsoPlexis (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing course of human health, in an all-stock transaction valued at $57.8 million. After the consummation of the transaction, the combined company will be named PhenomeX (Nasdaq: CELL) and will be a premier functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes. Details of the transaction and its rationale can be found here.

The Freshfields team is led by Partner Damien Zoubek, Counsel Oliver Board and Associates Victor Ma, Sofia Bernaciak, Anna Bensoussan and Jackson Myers on corporate and M&A matters; Partner Allison Liff and Senior Associate Aino Makisalo on financing matters; Partner Brandon Gantus, Senior Associate Andrew Herman and Associate Sonia Bennett on executive compensation and employee benefits matters; Partner Vinita Kailasanath, Associate Sora Park and Trainee Emily Parfitt on IP and life sciences matters; Partner Christine Lyon, Counsel Brock Dahl and Associate Christine Chong on privacy matters; Partner Joe Soltis and Associate Brendan Counihan on tax matters; and Partner Meghan Rissmiller, Special Counsel Meytal McCoy and Associate Lauren Vaca on antitrust matters.

ENDS